Reporting Hub https://www.jnj.com/johnson-johnson-announces-10-year-initiative-to-help-end-tuberculosis-the-worlds-1-infectious-killer https://www.jnj.com/johnson-johnson-announces-10-year-initiative-to-help-end-tuberculosis-the-worlds-1-infectious-killer https://www.jnj.com/johnson-johnson-commits-500-million-investment-over-four-years-to-help-end-the-epidemics-of-hiv-and-tuberculosis https://www.jnj.com/johnson-johnson-commits-500-million-investment-over-four-years-to-help-end-the-epidemics-of-hiv-and-tuberculosis https://www.jnj.com/u-s-fda-approves-new-pediatric-formulation-of-sirturoo-bedaquiline-as-part-of-combination-therapy-to-treat-children-with-pulmonary-multidrug-resistant-tuberculosis https://www.jnj.com/stop-tb-partnership-and-johnson-johnson-with-support-from-usaid-and-the-global-fund-announce-price-reduction-for-sirturo-bedaquiline-for-treatment-of-drug-resistant-tuberculosis-in-low-and-middle-income-countries https://www.jnj.com/health-for-humanity-goals-2025 New collaboration to treat TB: We were the founding members of the Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration), a consortium of philanthropic, nonprofit and private sector organizations aiming to accelerate the development of novel “pan-TB” drug regimens.